Half-Year 2022 Financial and Clinical Trials Update
PRED neuroscience development programs -1
Molecule
Indication
Phase # of patients
Status
Neuroscience
Brain Shuttle-gantenerumab (BS-
gantenerumab, RG6102)
Alzheimer's disease
lla
Brain Shuttle-CD20 (BS-CD20,
RG6035)
Multiple sclerosis
||
=
ralmitaront
(partial TAAR1 agonist, RG7906)
Schizophrenia
||
prasinezumab¹
||
=
(anti-aSynuclein, RG7935,
PRX002)
Parkinson's disease
llb
19
Roche
CT Identifier
~120
FPI Q1 2021
30
36
247
316
FPI Q3 2021
FPI Q4 2018; Recruitment completed Q3 2019
FPI Q4 2019
The study did not meet its primary endpoint, but
showed a reduced clinical decline of core motor
signs (MDS UPDRS partIII). Data presented at MDS
& ADPD 2020-22. The Open Label Extension is
ongoing.
NCT04639050
ISRCTN16295
177
NCT03669640
(TWAIN I)
NCT03100149
(PASADENA)
575
FPI Q2 2021
alogabat
(GABA-Aa5 PAM, RG7816)
NME (RG7637)
rugonersen
Autism spectrum disorder
||
105
FPI Q1 2021
Neurodevelopmental disorders
80
FPI Q3 2020
Angelman syndrome
66
FPI Q3 2020
(UBE3A LNA, RG6091)
NME (RG6182)
Neurodegenerative disorder
50
30
FPI Q4 2020
Partner: 1Prothena
BS Brain Shuttle
NCT04777331
(PADOVA)
NCT04299464
(Aurora)
NCT04475848
NCT04428281
152View entire presentation